<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug regimens for prophylaxis against malaria in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug regimens for prophylaxis against malaria in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drug regimens for prophylaxis against malaria in children</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Drug </td> <td class="subtitle1">Tablet size </td> <td class="subtitle1">Dose </td> <td class="subtitle1">Frequency* </td> <td class="subtitle1"> <p>Initiation</p> <p>(time before first exposure to malaria)</p> </td> <td class="subtitle1"> <p>Discontinuation</p> <p>(time after last exposure)</p> </td> </tr> <tr> <td class="subtitle2_left" colspan="6">Areas with chloroquine-resistant <em>Plasmodium falciparum </em></td> </tr> <tr> <td class="indent1">Atovaquone-proguanil (Malarone) </td> <td> <p>Pediatric tablet:</p> <p>62.5 mg atovaquone and 25 mg proguanil</p> <p>Adult tablet: </p> <p>250 mg atovaquone and 100 mg proguanil</p> </td> <td> <p>Body weight 5 to 8 kg, 1/2 pediatric tablet daily; </p> <p>Body weight 9 to 10 kg, 3/4 pediatric tablet daily; </p> <p>Body weight 11 to 20 kg, 1 pediatric tablet daily; </p> <p>Body weight 21 to 30 kg, 2 pediatric tablets daily; </p> <p>Body weight 31 to 40 kg, 3 pediatric tablets daily; </p> <p>Body weight ≥41 kg, 1 adult tablet daily</p> </td> <td>Once daily</td> <td>1 to 2 days</td> <td>7 days</td> </tr> <tr> <td class="indent1">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td> <p>Body weight ≤9 kg, 1/8 tablet or 5 mg salt per kg</p> <p>Body weight 10 to 19 kg, 1/4 tablet</p> <p>Body weight 20 to 30 kg, 1/2 tablet </p> <p>Body weight 31 to 45 kg, 3/4 tablet</p> <p>Body weight ≥46 kg, 1 tablet</p> </td> <td>Once weekly</td> <td>3 weeks preferable; 2 weeks acceptable</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>≥8 years old, 2 mg per kg of body weight orally once daily (maximum dose 100 mg/day)</td> <td>Once daily</td> <td>1 to 2 days</td> <td>4 weeks</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Areas with chloroquine-sensitive <em>P. falciparum </em></td> </tr> <tr> <td class="indent1">Chloroquine phosphate (Aralen and generic agents) </td> <td>500 mg salt (300 mg base)</td> <td>8.3 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>1 to 2 weeks</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Hydroxychloroquine sulfate (Plaquenil) </td> <td>400 mg salt (310 mg base)</td> <td>6.5 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>1 to 2 weeks</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Atovaquone-proguanil (Malarone) </td> <td>(as in 1st row above)</td> <td>(as in 1st row above)</td> <td>Once daily</td> <td>1 to 2 days</td> <td>7 days</td> </tr> <tr> <td class="indent1">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>(as in 2nd row above)</td> <td>Once weekly</td> <td>3 weeks preferable; 2 weeks acceptable</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>≥8 years old, 2 mg per kg of body weight orally once daily (maximum dose 100 mg/day)</td> <td>Once daily</td> <td>1 to 2 days</td> <td>4 weeks</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Areas with <em>Plasmodium vivax</em> </td> </tr> <tr> <td class="indent1">Primaquine phosphate for primary prophylaxis (off-label use)<sup>¶</sup></td> <td>26.3 mg salt (15 mg base)</td> <td>0.8 mg per kg of body weight salt (0.5 mg per kg of body weight base)</td> <td>Once daily</td> <td>1 to 2 days</td> <td>7 days</td> </tr> <tr> <td class="indent1">Chloroquine phosphate (Aralen and generic agents) </td> <td>500 mg salt (300 mg base)</td> <td>8.3 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>1 to 2 weeks</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Hydroxychloroquine sulfate (Plaquenil) </td> <td>400 mg salt (310 mg base)</td> <td>6.5 mg salt per kg of body weight (5 mg base per kg of body weight)</td> <td>Once weekly</td> <td>1 to 2 weeks</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Atovaquone-proguanil (Malarone) </td> <td>(as in 1st row above)</td> <td>(as in 1st row above)</td> <td>Once daily</td> <td>1 to 2 days</td> <td>7 days</td> </tr> <tr> <td class="indent1">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>(as in 2nd row above)</td> <td>Once weekly</td> <td>3 weeks preferable; 2 weeks acceptable</td> <td>4 weeks</td> </tr> <tr> <td class="indent1">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>≥8 years old, 2 mg per kg of body weight orally once daily (maximum dose 100 mg/day)</td> <td>Once daily</td> <td>1 to 2 days</td> <td>4 weeks</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Presumptive antirelapse therapy (to prevent relapse due to <em>P. vivax </em>or <em>P. ovale</em>) </td> </tr> <tr> <td class="indent1">Primaquine phosphate<sup>¶</sup></td> <td>26.3 mg salt (15 mg base)</td> <td>0.8 mg per kg of body weight salt (0.5 mg per kg of body weight base)</td> <td>Once daily</td> <td>As soon as possible following exposure for which another prophylactic drug taken</td> <td>14 days</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>G6PD: glucose-6-phosphate dehydrogenase.<br/>* Drugs administered once daily should be taken at the same time each day; drugs administered once weekly should be taken on the same day each week.<br/>¶ A quantitative G6PD test must be done to rule out G6PD deficiency prior to the first administration of primaquine or tafenoquine. Note that qualitative G6PD testing can miss those with moderate deficiency and is not sufficient to establish normal G6PD activity. Refer to the UpToDate text for further discussion.</p></div><div class="graphic_reference">1. Hill DR, Ericsson CD, Pearson RD, et al. The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.<br/>2. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.</div><div id="graphicVersion">Graphic 54777 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
